| Primary |
| Prophylaxis Against Transplant Rejection |
46.4% |
| Hypertension |
12.5% |
| Immunosuppressant Drug Therapy |
7.9% |
| Immunosuppression |
7.3% |
| Renal Transplant |
5.0% |
| Prophylaxis |
3.9% |
| Prophylaxis Against Renal Transplant Rejection |
2.7% |
| Diabetes Mellitus |
2.4% |
| Hypercholesterolaemia |
1.7% |
| Dyslipidaemia |
1.4% |
| Hyperlipidaemia |
1.4% |
| Infection Prophylaxis |
1.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.0% |
| Anaemia |
0.8% |
| Drug Use For Unknown Indication |
0.8% |
| Lymphangioleiomyomatosis |
0.8% |
| Antiviral Prophylaxis |
0.7% |
| Chronic Allograft Nephropathy |
0.7% |
| Depression |
0.7% |
| Lipids Increased |
0.7% |
|
| Focal Glomerulosclerosis |
10.3% |
| Kidney Transplant Rejection |
8.6% |
| Transplant Rejection |
8.6% |
| Diabetes Mellitus |
7.6% |
| Liver Transplant Rejection |
7.3% |
| Heart Transplant Rejection |
7.0% |
| Death |
6.6% |
| Prostate Cancer |
6.0% |
| Pyrexia |
4.3% |
| Proteinuria |
4.0% |
| Urinary Tract Infection |
4.0% |
| Renal Failure Acute |
3.6% |
| Ovarian Cyst |
3.0% |
| Pulmonary Cavitation |
3.0% |
| Venoocclusive Disease |
3.0% |
| Complications Of Transplant Surgery |
2.6% |
| Deep Vein Thrombosis |
2.6% |
| Gastroenteritis |
2.6% |
| Upper Respiratory Tract Infection |
2.6% |
| Vomiting |
2.6% |
|
| Secondary |
| Prophylaxis Against Transplant Rejection |
31.3% |
| Immunosuppression |
14.2% |
| Prophylaxis Against Renal Transplant Rejection |
10.9% |
| Product Used For Unknown Indication |
7.6% |
| Renal Transplant |
7.5% |
| Immunosuppressant Drug Therapy |
5.7% |
| Drug Use For Unknown Indication |
2.8% |
| Stem Cell Transplant |
2.7% |
| Hypertension |
2.6% |
| Prophylaxis Against Graft Versus Host Disease |
2.4% |
| Prophylaxis |
2.3% |
| Graft Versus Host Disease |
1.8% |
| Kidney Transplant Rejection |
1.7% |
| Antiretroviral Therapy |
1.3% |
| Liver Transplant |
1.0% |
| Heart Transplant |
1.0% |
| Histoplasmosis |
0.9% |
| Dyslipidaemia |
0.8% |
| Antibiotic Prophylaxis |
0.8% |
| Multiple Myeloma |
0.7% |
|
| Urinary Tract Infection |
19.1% |
| Prostate Cancer |
8.0% |
| Urinary Retention |
7.7% |
| Transplant Rejection |
7.3% |
| Thrombotic Microangiopathy |
5.8% |
| Kidney Transplant Rejection |
4.7% |
| Pneumonia |
4.7% |
| Urosepsis |
4.6% |
| Weight Increased |
4.3% |
| Heart Transplant Rejection |
3.7% |
| Sepsis |
3.6% |
| Pancytopenia |
3.4% |
| Diabetes Mellitus |
3.1% |
| Squamous Cell Carcinoma |
3.1% |
| Venoocclusive Disease |
3.1% |
| Death |
3.0% |
| Pyrexia |
3.0% |
| Pleural Effusion |
2.8% |
| Biliary Neoplasm |
2.5% |
| Vomiting |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.6% |
| Drug Use For Unknown Indication |
19.9% |
| Immunosuppression |
12.1% |
| Renal Transplant |
6.4% |
| Prophylaxis Against Graft Versus Host Disease |
5.8% |
| Prophylaxis Against Transplant Rejection |
4.8% |
| Prophylaxis |
4.6% |
| Immunosuppressant Drug Therapy |
3.8% |
| Heart Transplant |
3.5% |
| Liver Transplant |
2.2% |
| Stem Cell Transplant |
2.1% |
| Hypertension |
1.9% |
| Bone Marrow Conditioning Regimen |
1.7% |
| Chronic Graft Versus Host Disease |
1.7% |
| Nuclear Magnetic Resonance Imaging |
1.6% |
| Graft Versus Host Disease |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Diabetes Mellitus |
1.2% |
| Pneumonia |
1.0% |
| Antiviral Prophylaxis |
0.9% |
|
| Vomiting |
12.4% |
| Infection |
7.9% |
| Kidney Transplant Rejection |
7.3% |
| Multi-organ Failure |
6.7% |
| Nausea |
5.1% |
| Pyrexia |
5.1% |
| Renal Failure |
5.1% |
| Respiratory Failure |
5.1% |
| Transaminases Increased |
5.1% |
| Kaposi's Sarcoma |
4.5% |
| Pneumonia |
4.5% |
| Renal Impairment |
4.5% |
| Diarrhoea |
3.9% |
| Rectal Haemorrhage |
3.4% |
| Rhabdomyolysis |
3.4% |
| Thrombocytopenia |
3.4% |
| Thrombotic Microangiopathy |
3.4% |
| Transplant Rejection |
3.4% |
| Venoocclusive Liver Disease |
3.4% |
| Blood Creatinine Increased |
2.8% |
|
| Interacting |
| Product Used For Unknown Indication |
40.8% |
| Immunosuppression |
13.7% |
| Drug Use For Unknown Indication |
9.0% |
| Immunosuppressant Drug Therapy |
6.0% |
| Myocardial Infarction |
3.9% |
| Renal Transplant |
3.9% |
| Basal Cell Carcinoma |
3.0% |
| Convulsion |
2.6% |
| Grand Mal Convulsion |
2.6% |
| Aspergillus Infection |
2.1% |
| Haemophilus Infection |
2.1% |
| Bone Marrow Failure |
1.7% |
| Convulsion Prophylaxis |
1.7% |
| Lung Adenocarcinoma Stage Iv |
1.3% |
| Zygomycosis |
1.3% |
| Antifungal Prophylaxis |
0.9% |
| Cardiac Failure |
0.9% |
| Chemotherapy |
0.9% |
| Dyslipidaemia |
0.9% |
| Hypertension |
0.9% |
|
| Drug Interaction |
18.8% |
| Pneumonitis |
13.0% |
| Renal Impairment |
10.1% |
| Renal Failure |
7.2% |
| Drug Level Decreased |
5.8% |
| Pneumonia |
5.8% |
| Off Label Use |
4.3% |
| Rhabdomyolysis |
4.3% |
| Somnolence |
4.3% |
| Vomiting |
4.3% |
| Alveolitis |
2.9% |
| Drug Level Below Therapeutic |
2.9% |
| Hypokalaemia |
2.9% |
| Swelling Face |
2.9% |
| Swollen Tongue |
2.9% |
| Agranulocytosis |
1.4% |
| Dyspnoea Exertional |
1.4% |
| Malabsorption |
1.4% |
| Renal Failure Acute |
1.4% |
| Urinary Tract Infection |
1.4% |
|
